Merck KGaA will buy Silence Therapeutics and its siRNA pipeline for $1.3B
divesiranPositive
AI Analysis
Summary
Germany's Merck KGaA agreed to buy UK-based Silence Therapeutics for $1.3 billion to expand its rare and specialty disease work using genetic medicines. Silence is developing the siRNA drug divesiran.
Outcome Details
Merck KGaA agreed to acquire Silence Therapeutics for $1.3 billion
Importance:8/10
Sentiment:
0.60
M&AsiRNAgenetic medicinesrare diseasespecialty disease
Related Companies
Read the original article
Published by Endpoints News on October 19, 2026 1:57 PM